RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy

Talphera (NASDAQ:TLPH) was upgraded by RODMAN&RENSHAW to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other research firms also recently weighed in on TLPH. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Talphera in a research report on Tuesday, January 21st. Rodman & Renshaw initiated coverage on Talphera in a report on Tuesday. They set a “buy” rating and a $4.00 price objective on the stock. Finally, Maxim Group upgraded Talphera to a “strong-buy” rating in a research note on Friday, November 8th.

Talphera Stock Down 3.7 %

TLPH stock opened at $0.70 on Tuesday. The firm’s fifty day simple moving average is $0.65 and its two-hundred day simple moving average is $0.81. The stock has a market capitalization of $11.94 million, a price-to-earnings ratio of -1.02 and a beta of 0.28. Talphera has a twelve month low of $0.50 and a twelve month high of $1.61.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera makes up approximately 0.4% of Rosalind Advisors Inc.’s holdings, making the stock its 25th largest holding. Rosalind Advisors Inc. owned approximately 4.47% of Talphera as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.